methyl 2-chloro-5-hydrazinobenzoate hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-chloro-5-hydrazinobenzoate hydrochloride
• 英文别名: 2-chloro-5-hydrazino-benzoic acid methyl ester hydrochloride；methyl 2-chloro-5-hydrazinylbenzoate;hydrochloride
• 化学式: C₈H₉ClN₂O₂*ClH
• mdl: MFCD27756552
• 分子量: 237.086
• InChiKey: GYOFNTDZGUYRGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.97
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  64.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-chloro-5-hydrazinobenzoate hydrochloride 在 盐酸 、 二苯基膦叠氮化物 、 三乙胺 作用下， 以 水 、 甲苯 为溶剂， 反应 2.5h， 生成 2-chloro-5-(5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzoic acid methyl ester
  参考文献：
  名称：

  [EN] BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR
  [FR] INHIBITEURS BENZAMIDIQUES DU RECEPTEUR P2X7

  摘要：

  本发明提供了P2X7受体的苯甲酰胺抑制剂，其化学式为(I)，其中R1-R3如本文所定义。本发明的化合物可用于治疗IL-1介导的疾病，包括但不限于炎症性疾病，如骨关节炎和类风湿性关节炎；过敏、哮喘、慢性阻塞性肺疾病、癌症、缺血再灌注或中风或心脏病发作中的缺血症、自身免疫疾病和其他疾病。

  公开号：

  WO2004058731A1
• 作为产物：
  描述：

  2-氯-5-硝基苯甲酸甲酯 在 盐酸 、 sodium nitrate 、 tin(ll) chloride 作用下， 以 乙酸乙酯 为溶剂， 反应 4.0h， 生成 methyl 2-chloro-5-hydrazinobenzoate hydrochloride
  参考文献：
  名称：

  Structure–activity studies of a series of dipyrazolo[3,4- b :3′,4′- d ]pyridin-3-ones binding to the immune regulatory protein B7.1

  摘要：

  The interaction of co-stimulatory molecules on T cells with 137 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases. To this end, specific small molecule inhibitors of human B7.1 were identified and characterized. Herein, we report the identification of potent small molecule inhibitors of the B7.1-CD28 interaction. In a high-throughput screen we identified several leads that prevented the interaction of B7.1 with CD28 with activities in the nanomolar to low micromolar range. One of these, the dihydrodipyrazolopyridinone 1, was subsequently shown to bind the V-like domain of human B7.1 at equimolar stoichiometry. With this as a starting point, we report here the synthesis and initial in vitro structure-activity relationships of a series of these compounds. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00183-4

文献信息

• Benzamide inhibitors of the P2X7 receptor
  申请人：Dombroski A. Mark

  公开号：US20060217430A1

  公开（公告）日：2006-09-28

  The present invention provides benzamide inhibitors of the P2X 7 receptor of the formula: wherein R 1 -R 3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明提供了P2X7受体的苯甲酰胺抑制剂，其化学式如下：其中R1-R3如定义所示。本发明的化合物在治疗IL-1介导的疾病方面具有用途，包括但不限于炎症性疾病如骨关节炎和类风湿性关节炎；过敏、哮喘、慢性阻塞性肺疾病、癌症、脑卒中或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病。
• BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR
  申请人：Pfizer Products Inc.

  公开号：EP1581507A1

  公开（公告）日：2005-10-05
• US7071223B1
  申请人：——

  公开号：US7071223B1

  公开（公告）日：2006-07-04
• Structure–activity studies of a series of dipyrazolo[3,4- b :3′,4′- d ]pyridin-3-ones binding to the immune regulatory protein B7.1
  作者：Neal J. Green、Jason Xiang、Jing Chen、Lihren Chen、Audrey M. Davies、Dave Erbe、Steve Tam、James F. Tobin

  DOI：10.1016/s0968-0896(03)00183-4

  日期：2003.7

  The interaction of co-stimulatory molecules on T cells with 137 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases. To this end, specific small molecule inhibitors of human B7.1 were identified and characterized. Herein, we report the identification of potent small molecule inhibitors of the B7.1-CD28 interaction. In a high-throughput screen we identified several leads that prevented the interaction of B7.1 with CD28 with activities in the nanomolar to low micromolar range. One of these, the dihydrodipyrazolopyridinone 1, was subsequently shown to bind the V-like domain of human B7.1 at equimolar stoichiometry. With this as a starting point, we report here the synthesis and initial in vitro structure-activity relationships of a series of these compounds. (C) 2003 Elsevier Science Ltd. All rights reserved.
• [EN] BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR<br/>[FR] INHIBITEURS BENZAMIDIQUES DU RECEPTEUR P2X7
  申请人：PFIZER PROD INC

  公开号：WO2004058731A1

  公开（公告）日：2004-07-15

  The present invention provides benzamide inhibitors of the P2X7 receptor of the formula (I) wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明提供了P2X7受体的苯甲酰胺抑制剂，其化学式为(I)，其中R1-R3如本文所定义。本发明的化合物可用于治疗IL-1介导的疾病，包括但不限于炎症性疾病，如骨关节炎和类风湿性关节炎；过敏、哮喘、慢性阻塞性肺疾病、癌症、缺血再灌注或中风或心脏病发作中的缺血症、自身免疫疾病和其他疾病。